Genetic and genomic reports — reading the summary page

Almost every lab structures a genomic or genetic report the same way: patient and specimen details, the test method used, a results table listing the genes or biomarkers checked, and a therapy-association section flagging which findings connect to an approved drug or open clinical trial. Reference and limitation notes usually sit at the end. Once you know this order, you can go straight to the section that matters most instead of reading the whole document top to bottom.

• Patient & specimen information — the sample type, collection date and tumour content the lab used to run the test.
• Test methodology — which technology was used (commonly next-generation sequencing, or NGS) and how many genes the panel covers.
• Genes / biomarkers tested — the full panel list, which can run from a handful of genes to several hundred.
• Results table — every variant or biomarker value detected, usually with a tier or significance label next to each one.
• Therapy associations & trial matches — the section your oncologist reads most closely, listing any approved drug or open trial linked to a specific finding.

Genomic and genetic testing for CION patients is coordinated through accredited partner laboratories — this page explains the general layout and terminology; it does not interpret your specific report.

Bands and categories shown are the commonly cited AMP/ASCO/CAP and NCCN reference points used in patient education, indicative as of August 2026. Guidelines are updated periodically, and not every band applies to every cancer type — your oncologist confirms which fields are relevant to your specific report; this table is general education, not an eligibility statement.

1. 1

   Confirm the sample and test match what was ordered

   Check the specimen type, collection date and the test name against what your oncologist requested — a mismatch here is worth flagging before you read any further.

2. 2

   Go straight to the therapy-association section

   This is usually the shortest section and the one your oncologist reads most closely — it names any approved drug or open trial actually linked to a finding.

3. 3

   Note what's marked "not actionable" or VUS — without alarm

   These entries exist to be complete, not to warn you. A Tier III or Tier IV label does not, on its own, mean something is wrong.

4. 4

   Bring the full report, not a summary, to your next visit

   A molecular tumour board or your oncologist reads the complete document, including methodology and limitations — a partial printout can leave out context that changes what a finding means.

An actionable finding is a genetic change linked to an approved targeted therapy, immunotherapy or an open clinical trial for your specific cancer — it's what your oncologist is scanning the report for. An incidental finding is something detected along the way that isn't relevant to the current treatment decision: a variant in a gene unrelated to your cancer type, or occasionally a finding with implications for family members if it turns out to be inherited (germline).

Most items on a results table are neither — they're simply documented as part of a complete report. A long list of genes tested is not the same as a long list of treatment options, and a report with no actionable findings does not mean the testing "failed"; it means none of the genes checked matched an approved option at this time.

• Your treating oncologist — usually the first person to walk you through what applies to your case and what doesn't.
• A molecular tumour board — a panel that reviews the report as a team, discussing which findings are genuinely actionable before your consultation.
• A genetic counsellor — brought in specifically if a possible inherited (germline) finding is flagged, to explain what it may mean for you and your family.
• The reporting laboratory's molecular pathologist — the specialist who authored the report and can clarify technical questions your oncologist refers back to them.

• Where to Get Biomarker Testing Done in Hyderabad — which labs offer testing, the sample pathway, and typical turnaround.
• Can Biomarker Testing Be Repeated on a Newer Sample? — when a fresh sample is worth requesting instead of relying on an older report.
• Why Two Labs Gave Different PD-L1 Results — a closer look at one specific biomarker field that commonly appears on a genomic report.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through the biomarker and treatment-decision journey.

This page explains general genomic and genetic report terminology and layout for education only, and does not interpret any individual patient's report or confirm treatment eligibility. Genomic and genetic testing for CION patients is coordinated through accredited partner laboratories. Bring your full report to a consultation for a doctor's explanation of what it means for you.

Thousands of families have made sense of a genomic report with us

A dense report full of gene names and tier labels can feel overwhelming on your own. Our oncologists take the time to explain, in plain language, what applies to your case and what doesn't.